Severe headache in primary Sjögren’s syndrome treated with intrathecal rituximab

A severe and persistent migrainous headache in a patient with primary Sjøgren's syndrome unresponsive to treatment with immunosuppressive drugs, triptans, opioids, and NSAIDs, responded successfully to intrathecal B‐cell depletion with rituximab. We hypothesize that brain‐resident autoreactive...

Descripción completa

Detalles Bibliográficos
Autores principales: Tjensvoll, Anne Bolette, Lauvsnes, Maria Boge, Norheim, Katrine Brekke, Omdal, Roald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406134/
https://www.ncbi.nlm.nih.gov/pubmed/30899462
http://dx.doi.org/10.1002/ccr3.1987
_version_ 1783401231273689088
author Tjensvoll, Anne Bolette
Lauvsnes, Maria Boge
Norheim, Katrine Brekke
Omdal, Roald
author_facet Tjensvoll, Anne Bolette
Lauvsnes, Maria Boge
Norheim, Katrine Brekke
Omdal, Roald
author_sort Tjensvoll, Anne Bolette
collection PubMed
description A severe and persistent migrainous headache in a patient with primary Sjøgren's syndrome unresponsive to treatment with immunosuppressive drugs, triptans, opioids, and NSAIDs, responded successfully to intrathecal B‐cell depletion with rituximab. We hypothesize that brain‐resident autoreactive B cells were involved in headache pathogenesis and were eliminated by this procedure.
format Online
Article
Text
id pubmed-6406134
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-64061342019-03-21 Severe headache in primary Sjögren’s syndrome treated with intrathecal rituximab Tjensvoll, Anne Bolette Lauvsnes, Maria Boge Norheim, Katrine Brekke Omdal, Roald Clin Case Rep Case Reports A severe and persistent migrainous headache in a patient with primary Sjøgren's syndrome unresponsive to treatment with immunosuppressive drugs, triptans, opioids, and NSAIDs, responded successfully to intrathecal B‐cell depletion with rituximab. We hypothesize that brain‐resident autoreactive B cells were involved in headache pathogenesis and were eliminated by this procedure. John Wiley and Sons Inc. 2019-01-17 /pmc/articles/PMC6406134/ /pubmed/30899462 http://dx.doi.org/10.1002/ccr3.1987 Text en © 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Tjensvoll, Anne Bolette
Lauvsnes, Maria Boge
Norheim, Katrine Brekke
Omdal, Roald
Severe headache in primary Sjögren’s syndrome treated with intrathecal rituximab
title Severe headache in primary Sjögren’s syndrome treated with intrathecal rituximab
title_full Severe headache in primary Sjögren’s syndrome treated with intrathecal rituximab
title_fullStr Severe headache in primary Sjögren’s syndrome treated with intrathecal rituximab
title_full_unstemmed Severe headache in primary Sjögren’s syndrome treated with intrathecal rituximab
title_short Severe headache in primary Sjögren’s syndrome treated with intrathecal rituximab
title_sort severe headache in primary sjögren’s syndrome treated with intrathecal rituximab
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406134/
https://www.ncbi.nlm.nih.gov/pubmed/30899462
http://dx.doi.org/10.1002/ccr3.1987
work_keys_str_mv AT tjensvollannebolette severeheadacheinprimarysjogrenssyndrometreatedwithintrathecalrituximab
AT lauvsnesmariaboge severeheadacheinprimarysjogrenssyndrometreatedwithintrathecalrituximab
AT norheimkatrinebrekke severeheadacheinprimarysjogrenssyndrometreatedwithintrathecalrituximab
AT omdalroald severeheadacheinprimarysjogrenssyndrometreatedwithintrathecalrituximab

Ejemplares similares